经皮二尖瓣交界分离术与外科交界分离术治疗风湿性二尖瓣狭窄:随机对照试验的系统综述与荟萃分析
该系统综述与荟萃分析纳入7项随机对照试验共553例风湿性二尖瓣狭窄患者,比较经皮经静脉二尖瓣交界分离术(PTMC)与外科交界分离术(SC)的疗效、安全性和耐久性。汇总分析显示两组再狭窄或再干预风险、术后即刻二尖瓣面积、术后严重二尖瓣反流发生率及30个月时二尖瓣面积均无令人信服的差异。结论支持对瓣膜形态良好且年轻的患者继续推荐PTMC,因其围术期并发症较低。
要点
- PTMC与SC在再狭窄或再干预风险上无令人信服的差异,证据质量中等。
- 术后即刻二尖瓣面积、严重二尖瓣反流发生率及30个月时二尖瓣面积两组均无显著差异。
- 对瓣膜形态良好的年轻MS患者,PTMC因围术期并发症较低而仍应作为推荐。
核心结论
- 在缺乏SC优于PTMC的确凿证据前,结果支持对年轻且瓣膜形态良好的二尖瓣狭窄患者推荐PTMC,因其围术期并发症较低。
研究设计与样本
- 系统综述与荟萃分析,检索EMBASE、MEDLINE和WHO ICTRP注册库中比较PTMC与开放式和/或闭式二尖瓣交界分离术的随机对照试验。
- 共纳入7项随机对照试验,553例患者符合条件。
- 连续结局计算加权均数差(WMD),二分类结局计算相对风险(RR),采用随机效应模型合并,并用GRADE方法评估证据质量。
主要发现
- 再狭窄或再干预风险:PTMC组每100例减少15例,95%CI(-20至+8),证据质量中等。
- 术后即刻二尖瓣面积:WMD 0.15,95%CI(-0.18至0.48),证据质量极低。
- 术后严重二尖瓣反流发生率:PTMC组每100例增加3例,95%CI(-1至+10),证据质量中等。
- 30个月时二尖瓣面积两组无显著差异。
临床怎么用
- 对于年轻且瓣膜形态良好的风湿性二尖瓣狭窄患者,可继续将PTMC作为首选推荐,因其围术期并发症较低。
- 在与患者沟通时应说明PTMC与SC在再狭窄、再干预及严重二尖瓣反流风险上无令人信服的差异。
局限性
- 纳入的随机对照试验仅7项、共553例患者,样本量有限。
- 术后即刻二尖瓣面积结局的证据质量极低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Patients with severe mitral stenosis (MS) and their clinicians typically choose percutaneous transvenous mitral commissurotomy (PTMC) over surgical commissurotomy (SC). However, the durability of PTMC relative to SC is uncertain. We compared the efficacy, safety and durability of PTMC with SC for the treatment of MS. METHODS: We searched EMBASE, MEDLINE and WHO ICTRP registers for randomised controlled trials (RCTs) comparing PTMC, and open and/or closed mitral commissurotomy. The principal outcomes were rate of re-intervention and symptomatic improvement as inferred from the surrogate measures of immediate postprocedural mitral valve area (MVA), MVA at ≥6 month follow-up, incidence of mitral regurgitation (MR) and restenosis. We calculated weighted mean differences (WMD) for continuous outcomes, relative risks (RR) for binary outcomes and pooled outcomes using random-effects models and assessed the quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. RESULTS: Seven RCTs with 553 patients proved eligible. Pooled estimates showed no convincing difference in the risk of restenosis or re-intervention (15/100 fewer with PTMC, 95% CI (-20 to +8); quality of evidence: moderate) or in symptoms as inferred from immediate MVA (WMD 0.15, 95% CI (-0.18 to 0.48): very low), from the incidence of postprocedural severe MR (3/100 more with PTMC, 95% CI (-1 to +10): moderate) or from MVA at 30 months. CONCLUSION: Until data demonstrating convincing superiority of SC over PTMC become available, our results support the current practice of recommending PTMC to young patients with MS and favourable valve morphology, as it is associated with lower peri-procedural morbidity. PROSPERO REGISTRATION NUMBER: PROSPERO 2017 (CRD42017079512).
引用
- Singh AD, Mian A, Devasenapathy N, et al. Percutaneous mitral commissurotomy versus surgical commissurotomy for rheumatic mitral stenosis: a systematic review and meta-analysis of randomised controlled trials. Heart. 2020. PMID: 31974210. doi:10.1136/heartjnl-2019-315906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。